Simulations Plus, Inc. (NASDAQ:SLP) Short Interest Update

Simulations Plus, Inc. (NASDAQ:SLP) was the recipient of a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 2,844,266 shares, an increase of 59.7% from the July 15th total of 1,780,772 shares. Approximately 17.4% of the company’s shares are short sold. Based on an average daily volume of 542,524 shares, the days-to-cover ratio is currently 5.2 days.

Simulations Plus Stock Performance

SLP opened at $18.36 on Wednesday. The stock has a market capitalization of $371.33 million, a P/E ratio of 45.90 and a beta of 1.32. Simulations Plus has a 12 month low of $11.09 and a 12 month high of $21.01. The firm’s fifty day simple moving average is $18.12 and its 200 day simple moving average is $15.26.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.07. The firm had revenue of $21.89 million during the quarter, compared to analysts’ expectations of $20.90 million. Simulations Plus had a return on equity of 13.50% and a net margin of 9.88%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on SLP. Weiss Ratings raised shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 10th. Wall Street Zen cut shares of Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. William Blair downgraded Simulations Plus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 17th. Finally, Craig Hallum lowered Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 target price on the stock. in a report on Thursday, June 18th. Seven analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $17.25.

Insider Transactions at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 4,177 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total value of $77,023.88. Following the completion of the sale, the director owned 3,202,131 shares of the company’s stock, valued at approximately $59,047,295.64. This represents a 0.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.10% of the company’s stock.

Institutional Investors Weigh In On Simulations Plus

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in Simulations Plus during the second quarter worth $25,000. Quarry LP bought a new position in Simulations Plus in the third quarter valued at $28,000. GAMMA Investing LLC increased its stake in Simulations Plus by 26.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock valued at $52,000 after buying an additional 585 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Simulations Plus by 343.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock valued at $73,000 after buying an additional 3,084 shares during the last quarter. Finally, Longfellow Investment Management Co. LLC bought a new stake in Simulations Plus during the 2nd quarter worth about $77,000. Institutional investors and hedge funds own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.